Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Related AZN
AstraZeneca to Present Data Demonstrating Diversity of Its Portfolio of Innovative Formulations and Devices at the European Respiratory Society International Congress 2015
Biotechs Coming Off One Of The Busiest Weeks In Recent Memory
Bristol-Myers to Pay $14M to Settle China Bribe Charges (Zacks)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

Sep 2015Deutsche BankUpgradesHoldBuy
Sep 2015HSBCUpgradesHoldBuy
Jul 2015BerenbergUpgradesHoldBuy

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings


Related Articles (AZN)

Get Benzinga's Newsletters